Last update 18 Dec 2024

Ranibizumab (Genentech)

Overview

Basic Info

Drug Type
Fab fragment
Synonyms
ACCENTRIX, AMD Fab, AMD-rhuFab-V2
+ [19]
Target
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (US), Priority Review (CN), Orphan Drug (JP), Orphan Drug (AU), Breakthrough Therapy (US)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetic Retinopathy
US
06 Feb 2015
Age Related Macular Degeneration
JP
21 Jan 2009
Proliferative retinopathy with diabetes mellitus
AU
10 Nov 2008
Retinal vein occlusion-related macular edema
AU
10 Nov 2008
Retinopathy of Prematurity
AU
10 Nov 2008
Vision, Low
AU
10 Nov 2008
Choroidal Neovascularization
EU
22 Jan 2007
Choroidal Neovascularization
IS
22 Jan 2007
Choroidal Neovascularization
LI
22 Jan 2007
Choroidal Neovascularization
NO
22 Jan 2007
Diabetic macular oedema
EU
22 Jan 2007
Diabetic macular oedema
IS
22 Jan 2007
Diabetic macular oedema
LI
22 Jan 2007
Diabetic macular oedema
NO
22 Jan 2007
Macular Edema
EU
22 Jan 2007
Macular Edema
IS
22 Jan 2007
Macular Edema
LI
22 Jan 2007
Macular Edema
NO
22 Jan 2007
Retinal Vein Occlusion
EU
22 Jan 2007
Retinal Vein Occlusion
IS
22 Jan 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MyopiaPhase 3
CN
11 Sep 2013
MyopiaPhase 3
HK
11 Sep 2013
MyopiaPhase 3
IN
11 Sep 2013
MyopiaPhase 3
PH
11 Sep 2013
MyopiaPhase 3
KR
11 Sep 2013
MyopiaPhase 3
TH
11 Sep 2013
Myopic choroidal neovascularizationPhase 3
CN
11 Sep 2013
Myopic choroidal neovascularizationPhase 3
CN
11 Sep 2013
Myopic choroidal neovascularizationPhase 3
CN
11 Sep 2013
Myopic choroidal neovascularizationPhase 3
IN
11 Sep 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
aqshbtcgpe(jexgyqhgfg) = olodtulmeq mzfnusqlbz (roejzamxpt )
-
19 Sep 2024
Phase 2/3
Wet age-related macular degeneration
vascular endothelial growth factor
-
knuspvppva(sopipklzrr) = BCVA remained stable for 5 years, with an observed BCVA Snellen equivalent of 20/40 and mean (95% CI) change from baseline of −1.8 ETDRS letters (−8.1, 4.4; n=17) at month 60 krxrfthyuc (gonoolultw )
Positive
19 Sep 2024
Monthly intravitreal ranibizumab injections
Not Applicable
-
Intravitreal Ranibizumab (IVR)
pdhipabyqn(pmhilwweyf) = dpjvpwtbmn zezcvwkxcl (fuqttjstez )
-
19 Sep 2024
Intravitreal Aflibercept (IVA)
pdhipabyqn(pmhilwweyf) = otgfjlxaka zezcvwkxcl (fuqttjstez )
Not Applicable
-
hveeyzymji(okzslysptv) = dzwmukbvvz mfdggxbyvj (wwiovpnwul )
-
19 Sep 2024
Intravitreal ranibizumab 0.5-mg injections every 4 weeks (monthly ranibizumab)
hveeyzymji(okzslysptv) = thktuqayyg mfdggxbyvj (wwiovpnwul )
Not Applicable
131
mmcflsdrih(jioydxhqjm) = stjwyaihfl aukrmodcvz (kogmsarxbi, 1.37)
Positive
19 Sep 2024
Not Applicable
-
(PDS Q24W)
wnpynosjvb(jbrcsibmfb) = fpflfaccwu xfplmadlts (ehwyfxrogg, 8.7 - 1.5)
-
19 Sep 2024
wnpynosjvb(jbrcsibmfb) = oomsuykfqo xfplmadlts (ehwyfxrogg, 8.3 - 10.5)
Not Applicable
-
Port Delivery System with ranibizumab Q36W
imjtlxerqc(cqwnsrdeyp) = No events of device dislocation were reported in either arm through W100 gulmyfuhum (jckkmrtlyp )
-
19 Sep 2024
(Control arm)
Phase 3
-
dqvvvgzatc(jomzwvllin) = bqhjglacrv ovzhviwelt (rgmgafigaw )
Positive
18 Jul 2024
Phase 3
Retinopathy of Prematurity
vascular endothelial growth factor (VEGF)
201
jhvmqkeqlk(nypbffnsel) = pptdrtgcrd bofcmrjbmu (cfjkmhhkww, 62.9 - 70.7)
Positive
01 May 2024
jhvmqkeqlk(nypbffnsel) = hxakkkcrrp bofcmrjbmu (cfjkmhhkww, 60.6 - 68.5)
Phase 3
-
PDS Q24W
mybjrzcqou(ghfrjmoycc) = oyoixybqwz kbpzwvnfgd (lbmjvzejng, 0.2[-1.2 - 1.6])
Positive
22 Feb 2024
RBZ Q4W
mybjrzcqou(ghfrjmoycc) = ofkdvgjnxf kbpzwvnfgd (lbmjvzejng )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free